ABBV News
AbbVie Inc.
$284.98
-$0.21(-0.08%)
58
Overall
60
Value
66
Tech
50
Quality
Market Cap
$503.96B
Volume
1.46M
52W Range
$190.75 - $291.40
Target Price
$282.37
ABBV news: the latest AbbVie Inc. headlines, press releases and market updates, newest first.
Latest ABBV News
- AbbVie Targets Essential Tremor With New Mid-Stage Trial, Adding Depth to Its Neurology PipelineTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 22, 2026
- AbbVie Halts Early-Stage Liver Cancer Combo Trial: What It Means for ABBV InvestorsTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 21, 2026
- Barclays Reaffirms Their Buy Rating on AbbVie (ABBV)TipRanks Auto-Generated Intelligence Newsdesk · Oct 21, 2026
- Citi Sticks to Their Hold Rating for AbbVie (ABBV)TipRanks Auto-Generated Intelligence Newsdesk · Oct 20, 2026
- Citi Sticks to Their Hold Rating for AbbVie (ABBV)TipRanks Auto-Generated Intelligence Newsdesk · Oct 20, 2026
- AbbVie (ABBV) Receives a Buy from RBC CapitalTipRanks Auto-Generated Intelligence Newsdesk · Oct 20, 2026
- AI Cancer-Fighting Iambic Therapeutics Stock (IAM) Rockets 13% After $150M IPODavid Craik · Oct 15, 2026
- AbbVie Targets Head and Neck Cancer With New Telisotuzumab Combo TrialTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 13, 2026
- The Week That Was, The Week Ahead: Macro and Markets, October 11Ran Melamed · Oct 11, 2026
- Looking for Dividend Aristocrats? These 3 Healthcare Stocks Deserve a Closer LookSukanya Varma · Oct 9, 2026
- AbbVie Targets Jawline and Neck Aesthetics With New Botox and Juvéderm StudyTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 8, 2026
- AbbVie’s Venetoclax AML Study in Greece: What the Latest Update Means for InvestorsTipRanks Clinical-Trials-Auto-Generated Newsdesk · Oct 2, 2026
- Analysts Offer Insights on Healthcare Companies: Kura Oncology (KURA) and AbbVie (ABBV)TipRanks Newsroom · Oct 1, 2026
- AbbVie Wraps Key Early Trial on ABBV-722 Drug Interaction, Supporting Pipeline ConfidenceTipRanks Clinical-Trials-Auto-Generated Newsdesk · Sep 30, 2026
- AbbVie’s Bretisilocin Study Completion Signals Quiet Progress in Early-Stage PipelineTipRanks Clinical-Trials-Auto-Generated Newsdesk · Sep 30, 2026
- Wall Street Analysts Are Bullish on Top Healthcare PicksTipRanks Newsroom · Sep 29, 2026
- Citi Keeps Their Hold Rating on AbbVie (ABBV)TipRanks Auto-Generated Intelligence Newsdesk · Sep 29, 2026
- RBC Capital Sticks to Its Buy Rating for AbbVie (ABBV)TipRanks Auto-Generated Intelligence Newsdesk · Sep 24, 2026
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ABBV | $284.98 | -0.1% | 1.46M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |